Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Structure Therapeutics Inc.

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
Structure Therapeutics to Participate in the Jefferies London Healthcare Conference
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
Structure Therapeutics Appoints Angus C. Russell to Board of Directors
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
Structure Therapeutics Announces Participation in Upcoming Investor Conferences
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
Structure Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
Structure Therapeutics Announces $300 Million Private Placement Equity Financing
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
Structure Therapeutics Appoints Ted W. Love, M.D., to Board of Directors
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
Structure Therapeutics to Present at Jefferies Healthcare Conference
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
Structure Therapeutics Announces Poster Presentations at the American Thoracic Society International Conference
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
Structure Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
Structure Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
Structure Therapeutics Announces Pricing of Upsized Initial Public Offering
From Structure Therapeutics Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.